# Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

> **NCT01763905** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 307 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Placebo to Evolocumab
- **DRUG:** Ezetimibe
- **DRUG:** Placebo to Ezetimibe

## Key facts

- **NCT ID:** NCT01763905
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-24
- **Primary completion:** 2013-11-19
- **Final completion:** 2013-11-19
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2020-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01763905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01763905, "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01763905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*